Science Current Events | Science News | Brightsurf.com
 

Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC

April 04, 2012
CHICAGO - Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with belagenpumatucel-L, a therapeutic vaccine. The findings were presented here at the AACR Annual Meeting 2012, held March 31 - April 4.

"This is a novel immunotherapy that appears to show unusually long survival in some patients," said Lyudmila Bazhenova, M.D., associate clinical professor at the University of California-San Diego Moores Cancer Center in La Jolla, Calif.

These findings represent an updated long-term survival analysis on patients treated with belagenpumatucel-L, a cell-based allogeneic vaccine derived from four lung cancer cell lines. The open-label study included 75 patients with non-small cell lung cancer (NSCLC) - two patients with stage 2 disease, 12 with stage 3A, 15 with stage 3B and 46 with stage 4. The researchers randomly assigned patients to three dose cohorts: 1.25, 2.5 or 5 × 107 cells/injection.

For all patients, median survival was 14.5 months, and the five-year survival rate was 20 percent. The 40 patients with stage 3B/4 cancer enrolled in the second and third dose cohorts had a median survival of 15.9 months and a one-year survival rate of 61 percent, a two-year survival rate of 41 percent and a five-year survival rate of 18 percent.

Patients with stage 3B/4 nonprogressive disease after chemotherapy had a median survival of 44.4 months; five-year survival was 50 percent, which is "unheard of for patients with NSCLC," Bazhenova said.

In contrast, patients who progressed after front-line chemotherapy had a median survival rate of 14.1 months and a 9.1 percent five-year survival rate.

Bazhenova said that although these results are intriguing, they must be confirmed in a phase III clinical trial, which is currently under way in eight countries.

American Association for Cancer Research


Related Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles


ASTRO issues guideline on definitive and adjuvant RT for locally advanced non-small cell lung cancer
The American Society for Radiation Oncology (ASTRO) is issuing a new guideline, "Definitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer: An American Society for Radiation Oncology (ASTRO) evidence-based clinical practice guideline."

Multiple types of resistance to new lung cancer drug identified
After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

Profiling approach to enable right lung cancer treatment match
Manchester researchers have tested a new way to genetically profile lung cancer samples, potentially allowing doctors to more easily identify the most appropriate treatment for patients.

Pneumonectomy or lobectomy?
For patients in the early stage of non-small cell lung cancer, surgical resection yields optimal outcomes. Prior investigations have shown that different resection procedures have very different outcomes, with pneumonectomy associated with three-fold higher mortality than other resection types.

MD Anderson study points to potential new lung cancer therapy
New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

Driver of non-small cell lung cancer, FGFR1, also in 23 percent of small cell lung cancer
Significant new treatments are available or in clinical trials for non-small cell lung cancer. The same explosion in treatment options is not true for the disease's cousin, small cell lung cancer, the less common and more aggressive form of the disease.

Anti-fungal drug shows promise as potential new cancer treatment
A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.

Socioeconomic factors affect odds of death after a lung cancer operation
People with limited education and low income have higher odds of death within 30 days after undergoing an operation for lung cancer than those who are more educated and financially better off.

Nintedanib in lung cancer: Added benefit depends on disease severity
Since November 2014 nintedanib (trade name: Vargatef) has been approved in combination with docetaxel for the treatment of adults with advanced non-small cell lung cancer (NSCLC) of the glandular tissue (adenocarcinoma) who have already received chemotherapy.

No association between lung cancer risk in women and reproductive history or hormone use
The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for a role of hormone use in the incidence of lung cancer.
More Non-small Cell Lung Cancer Current Events and Non-small Cell Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Management of N2/IIIA Non-Small-cell Lung Cancer, An Issue of Thoracic Surgery Clinics, 1e (The Clinics: Surgery)

Management of N2/IIIA Non-Small-cell Lung Cancer, An Issue of Thoracic Surgery Clinics, 1e (The Clinics: Surgery)
by Mithran Sukumar (Author)


This issue of the Thoracic Surgery Clinics is devoted to Management of N2/IIIA Lung Cancer and will address the following topics: Defining N2 disease; molecular detection and immunocytochemistry of N2 disease; radiographic staging of N2 disease; minimally invasive staging of N2 disease (EBUS/EUS, mediastinoscopy and VATS ); intraoperative staging and surgical management of N2 disease; definitive chemo/RT for N2 disease; neoadjuvant therapy for N2 disease; restaging after neoadjuvant therapy for N2 disease; adjuvant therapy for N2 disease; and management algorithms for N2 disease.

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer

OPDIVO (Nivolumab): Treats unresectable or Metastatic Melanoma (skin cancer) and Metastatic Squamous Non-Small Cell Lung Cancer
by James Lee Anderson (Author)


“Although, your health condition may impact your everyday life, do not let it define who you are.” OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. OPDIVO (nivolumab) is also indicated for the treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. OPDIVO (nivolumab) treat your melanoma or lung cancer by working with your immune system. OPDIVO can cause your immune system to attack normal organs and tissues in many areas of your body and can affect the way they work. These problems can sometimes become serious or life-threatening and can lead to...

Medifocus Guidebook on: Non-Small Cell Lung Cancer

Medifocus Guidebook on: Non-Small Cell Lung Cancer
by Medifocus.com (Author), Elliot Jacob PhD. (Editor)


The MediFocus Guidebook on Non-Small Cell Lung Cancer is the most comprehensive, up-to-date source of information available. You will get answers to your questions, including risk factors of Non-Small Cell Lung Cancer, standard and alternative treatment options, leading doctors, hospitals and medical centers that specialize in Non-Small Cell Lung Cancer, results of the latest clinical trials, support groups and additional resources, and promising new treatments on the horizon. This one of a kind Guidebook offers answers to your critical health questions including the latest treatments, clinical trials, and expert research; high quality, professional level information you can trust and understand culled from the latest peer-reviewed journals; and a unique resource to find leading experts,...

  QuickFACTS™ Non-Small Cell Lung Cancer, Third Edition - 2015: What You Need to Know - Now
by American Cancer Society


According to estimates, more than 244,000 new cases of lung cancer will be diagnosed in the United States this year; of those 85 to 90 percent will be non-small cell lung cancer. There are three main subtypes of this lung cancer, including squamous cell (epidermoid) carcinoma, adenocarcinoma, and large cell (undifferentiated) carcinoma. The cells in these subtypes look very different under a microscope, but the approach to treating them is often very similar. This QuickFACTS reference book on non-small cell lung cancer covers everything from risk factors for the disease to living well after treatment, with sections on the causes of non-small cell lung cancer, early detection, diagnosis and staging, and treatment. An essential guide for a newly diagnosed patient, this book covers the...

Management of Stage I Non-Small Cell Lung Cancer, An Issue of Thoracic Surgery Clinics, 1e (The Clinics: Surgery)

Management of Stage I Non-Small Cell Lung Cancer, An Issue of Thoracic Surgery Clinics, 1e (The Clinics: Surgery)
by Rodney J. Landreneau MD (Author)


[Thoracic Surgery Clinics, Volume 17, Number 2> Univ. of Pittsburgh, PA. Topics include the role of CT screening for lung cancer, CT-directed diagnosis of peripheral lung lesions suspicious for cancer, bronchoscopic-directed diagnosis of peripheral lung lesions suspicious for cancer, prognostic modeling in early stage lung cancer, and more. For clinicians.

Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene (SpringerBriefs in Applied Sciences and Technology / Forensic and Medical Bioinformatics)

Bioinformatics of Non Small Cell Lung Cancer and the Ras Proto-Oncogene (SpringerBriefs in Applied Sciences and Technology / Forensic and Medical Bioinformatics)
by Amita Kashyap (Author), D. Bujamma (Author), Naresh Babu M (Author)


Cancer is initiated by activation of oncogenes or inactivation of tumor suppressor genes. Mutations in the K-ras proto-oncogene are responsible for 10–30% of adenocarcinomas. Clinical Findings point to a wide variety of other cancers contributing to lung cancer incidence. Such a scenario makes identification of lung cancer difficult and thus identifying its mechanisms can contribute to the society. Identifying unique conserved patterns common to contributing proto-oncogenes may further be a boon to Pharmacogenomics and pharmacoinformatics. This calls for ab initio/de novo drug discovery that in turn will require a comprehensive in silico approach of Sequence, Domain, Phylogenetic and Structural analysis of the receptors, ligand screening and optimization and detailed Docking...

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians

21st Century Adult Cancer Sourcebook: Non-Small Cell Lung Cancer (NSCLC) - Clinical Data for Patients, Families, and Physicians
by Progressive Management


Authoritative information and practical advice from the nation's cancer experts about non-small cell lung cancer (NSCLC) includes official medical data on signs, symptoms, early detection, diagnostic testing, risk factors and prevention, treatment options, surgery, radiation, drugs, chemotherapy, staging, biology, prognosis, and survival, with a complete glossary of technical medical terms and current references.

Starting with the basics, and advancing to detailed patient-oriented and physician-quality information, this comprehensive in-depth compilation gives empowered patients, families, caregivers, nurses, and physicians the knowledge they need to understand the diagnosis and treatment of non-small cell lung cancer (NSCLC).

Non-small cell lung cancer is a disease...

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)

Systemic Treatment of Non-Small Cell Lung Cancer (Oxford Oncology Library)
by Giuseppe Giaccone (Author)


Lung cancer is the leading cause of cancer mortality worldwide, and non-small cell lung cancer (NSCLC) accounts for about 85% of all cases of lung cancer. Most patients present with advanced disease and five-year survival is low at about 15%. Surgery is the main treatment for early stage disease. If patients are deemed inoperable, systemic chemotherapy is considered. For patients with locally advanced disease, multimodality therapy is administered where chemotherapy is given in combination with definitive radiation therapy or surgery in selected cases. Cytotoxic chemotherapy regimens mainly consist of a platinum doublet. Biologic agents are increasingly being incorporated into treatment regimens.

This pocketbook summarises the latest evidence-based and practical information on the...

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!

What You Need to Know About Non-Small Cell Lung Cancer - It's Your Life, Live It!
by Cancer Group Institute


Selecting the right treatment can literally make the difference between life and death. It is important to have the peace-of-mind knowing that you have done everything possible to help fight Non-Small Cell Lung cancer successfully.

The Cancer Group Institute's book explains, in plain English, the definition, types, frequency, risk factors, symptoms, historic and latest effective treatment for Non-Small Cell Lung cancer. We describe surgery, radiation, chemotherapy and immune therapies. We tell you everything you must know to help make the right choices today for a Non-Small Cell Lung cancer problem.

We are honored to inform you that many leading hospitals use our books in their medical library to be used by physicians. They are Harvard University, Columbia, NYU, ...

© 2015 BrightSurf.com